A new decision model for economic evaluation of novel therapies for HCV

A new decision model for economic evaluation of novel therapies for HCV

In 2014, the European Medicines Agency (EMA) has given the license to two new direct-acting antiviral: sofosbuvir and simeprevir. The evidence provided by the studies, reported a high rate of SVR even in patients with decompensated cirrhosis. This and other innovative elements are potentially adept...

Full description

Bibliographic Details
Main Authors: Matteo Ruggeri, Americo Cicchetti, Silvia Coretti, Carlo Cammà, Nicola Caporaso, Antonio Gasbarrini
Format: Article
Language:English
Published: SEEd Medical Publishers 2014-09-01
Series:Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:
wef model
economic evaluation
hcv
Online Access:https://journals.seedmedicalpublishers.com/index.php/FE/article/view/945

Similar Items

Similar Items